About Liquidia
PRINT Technology
Pipeline
Investors
Newsroom
Careers
Contact Us

About Liquidia
PRINT Technology
Pipeline
Investors
Newsroom
Careers
Contact Us

Newsroom

Newsroom

December 14, 2020
Liquidia Corporation Announces Chief Executive Officer Transition
November 30, 2020
Liquidia Corporation Appoints Michael Kaseta Chief Financial Officer
November 25, 2020
Liquidia Receives Complete Response Letter from FDA for LIQ861 (treprostinil) Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension

Newsroom
Press Release Archives
Media Contact

Home
About Liquidia
— Leadership
— Board of Directors
— Collaborations
— Business Development

PRINT Technology
— Publications

Pipeline
— LIQ861
— LIQ865

Investors

Newsroom
— Media Contact

Contact
— General Inquiries
— Map/Directions

Careers
— Career Opportunities
— Life at Liquidia
— Benefits

Liquidia is a late-stage clinical biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary PRINT® technology to transform the lives of patients. Currently, Liquidia is focused on the development of two product candidates using its PRINT® particle engineering platform: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain.

PO Box 110085, Research Triangle Park, NC 27709

Tel +1 919-328-4400

Fax +1 919-328-4402

© 2021 Liquidia Corporation

Legal Privacy Cookies Social Media